for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Basilea Pharmaceutica AG

BSLN.S

Latest Trade

44.18CHF

Change

0.14(+0.32%)

Volume

15,463

Today's Range

43.70

 - 

44.38

52 Week Range

29.28

 - 

61.20

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
44.04
Open
44.30
Volume
15,463
3M AVG Volume
1.62
Today's High
44.38
Today's Low
43.70
52 Week High
61.20
52 Week Low
29.28
Shares Out (MIL)
10.80
Market Cap (MIL)
550.54
Forward P/E
--
Dividend (Yield %)
--

Next Event

Full Year 2020 Basilea Pharmaceutica AG Earnings Release

Latest Developments

More

Basilea Presents Preclinical Data On Derazantinib

Basilea Reports Interim Results From Phase 1/2 Study FIDES-02

Basilea Reports Antitumor Efficacy Of Derazantinib

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.

Industry

Biotechnology & Drugs

Contact Info

Grenzacherstrasse 487

4058

Switzerland

+41.61.6061111

http://www.basilea.com/

Executive Leadership

Domenico Scala

Chairman of the Board of Directors

David Veitch

Chief Executive Officer, Member of the Management Committee

Thomas Werner

Vice Chairman of the Board of Directors

Adesh Kaul

Member of the Management Committee, Chief Financial Officer

Gerrit Hauck

Member of the Management Committee, Chief Technology Officer

Key Stats

2.13 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (CHF)

2017

-1.790

2018

-2.890

2019

-2.080

2020(E)

-1.060
Price To Earnings (TTM)
173.81
Price To Sales (TTM)
4.45
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
118.37
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
1.88
Return on Equity (TTM)
1.36

Latest News

Latest News

BRIEF-Basilea Starts Offer Period Of Its Partial Repurchase Offer

* BASILEA ANNOUNCES THE START OF THE OFFER PERIOD OF ITS PARTIAL REPURCHASE OFFER FOR ITS OUTSTANDING CONVERTIBLE BONDS DUE 2022

BRIEF-Basilea To Move Headquarters To Allschwil

* BASILEA ANNOUNCES MOVE OF CORPORATE HEADQUARTERS TO ALLSCHWIL, CANTON OF BASEL-LANDSCHAFT, IN 2022 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Basilea Announces Partial Repurchase Offer For At Least CHF 90 Million

* BASILEA ANNOUNCES PARTIAL REPURCHASE OFFER FOR AT LEAST CHF 90 MILLION AND UP TO CHF 110 MILLION IN PRINCIPAL AMOUNT OF ITS OUTSTANDING CONVERTIBLE BONDS DUE 2022

BRIEF-Basilea Successfully Places CHF 125 Million Senior Convertible Bonds

* BASILEA SUCCESSFULLY PLACES CHF 125 MILLION SENIOR CONVERTIBLE BONDS

BRIEF-Basilea Places CHF 100 Mln Senior Convertible Bonds

* BASILEA LAUNCHES THE PLACEMENT OF CHF 100 MILLION SENIOR CONVERTIBLE BONDS WITH AN INCREASE OPTION OF CHF 25 MILLION

BRIEF-Basilea Enters Into Sale And Leaseback Agreement For Corporate Headquarters Building

* BASILEA ENTERS INTO SALE AND LEASEBACK AGREEMENT FOR CORPORATE HEADQUARTERS BUILDING

BRIEF-Basilea Pharmaceutica Receives CHF 5 Million Milestone Payment

* BASILEA RECEIVES CHF 5 MILLION MILESTONE PAYMENT RELATED TO MARKETING AUTHORIZATION OF ANTIFUNGAL CRESEMBA® IN RUSSIA

BRIEF-Basilea Says FDA Approves Protocol Amendment For Phase 3 Ceftobiprole Study

* FDA APPROVES PROTOCOL AMENDMENT FOR PHASE 3 ERADICATE BACTEREMIA STUDY WITH CEFTOBIPROLE TO INCLUDE A BROADER SPECTRUM OF SEVERELY ILL PATIENTS

BRIEF-Basilea Sees No Indication Of Negative Impact On Prescriptions For Cresemba, Zevtera

* BASILEA SHAREHOLDERS APPROVE ALL PROPOSALS OF THE BOARD OF DIRECTORS AT THE ANNUAL GENERAL MEETING

BRIEF-Basilea First Milestone Payment Related To Launch Of Antifungal Cresemba In Australia

* BASILEA REPORTS THE LAUNCH OF ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) IN AUSTRALIA TRIGGERING THE FIRST MILESTONE PAYMENT RELATED TO ASIA-PACIFIC

BRIEF-Basilea FY Net Loss Narrows To CHF 22.4 Million

* FY OPERATING LOSS -17.2 MILLION CHF VERSUS -24.1 MILLION CHF LOSS YEAR AGO

BRIEF-Basilea Reports Activity Of Derazantinib In Preclinical Models Of Gastric Cancer

* BASILEA REPORTS ACTIVITY OF DERAZANTINIB IN PRECLINICAL MODELS OF GASTRIC CANCER AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Basilea Announces Agreement For Fides-03 Study With Derazantinib In Gastric Cancer

* ANNOUNCES CLINICAL SUPPLY AGREEMENT FOR ITS PLANNED STUDY FIDES-03 WITH DERAZANTINIB IN GASTRIC CANCER

BRIEF-Basilea FY 2019 Total Revenue Expected To Increase To About CHF 134 Mln

* BASILEA REPORTS TOTAL REVENUE EXCEEDING GUIDANCE DRIVEN BY HIGHER THAN EXPECTED CONTRIBUTIONS FROM CRESEMBA® AND ZEVTERA® IN 2019

BRIEF-Basilea To Progress With Lisavanbulin To Phase 2 Study

* BASILEA PLANS PROGRESSION OF ONCOLOGY CANDIDATE LISAVANBULIN TO TARGETED, BIOMARKER-DRIVEN PHASE 2 STUDY

BRIEF-Basilea Pharmaceutica Says H1 Net Loss Narrows To CHF 15.4 Mln

* BASILEA REPORTS SIGNIFICANTLY INCREASED CASH-GENERATING REVENUE, FLAT OPERATING EXPENSES AND REDUCED NET LOSS FOR HALF-YEAR 2019

BRIEF-Basilea Starts Phase 1/2 Study With Derazantinib In Urothelial Cancer

* BASILEA STARTS PHASE 1/2 STUDY WITH DERAZANTINIB IN UROTHELIAL CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer

* BASILEA EXTENDS PHASE 2 STUDY WITH DERAZANTINIB IN INTRAHEPATIC BILE DUCT CANCER (ICCA) TO INCLUDE PATIENTS WITH FGFR2 GENE MUTATIONS OR AMPLIFICATIONS

BRIEF-Basilea Pharmaceutica Publishes Clinical Data For Anticancer Drug Candidates BAL101553

* REPORTS PUBLICATION OF CLINICAL DATA FOR ANTICANCER DRUG CANDIDATES BAL101553 IN GLIOBLASTOMA AND DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million

* BASILEA REPORTS STRONG REVENUE GROWTH AND SIGNIFICANT PIPELINE PROGRESS FOR FULL-YEAR 2018

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up